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Abstract
Chaperone-mediated autophagy (CMA) is a mechanism by which individual pro-
teins are selectively bound to chaperones to be translocated across and degraded
in the lysosome. We have previously reported that long-lived mouse models have
been known to have constitutive upregulation of CMA and also increased AKT
phosphorylation. GFAP is one of the only known regulators of chaperone-mediated
autophagy, which itself is regulated by AKT. We have found that inhibiting the In-
sulin/PI3K/AKT pathway by using PI3K inhibitors and PDK-1 inhibitors decreases
both AKT and subsequent GFAP phosphorylation in vitro and in vivo. We con-
firmed that this pathway stimulates chaperone-mediated autophagy independently
of other autophagic pathways such as macroautophagy. Lastly, we also report that
AMPK has been found to play a role of regulating CMA via the Insulin/PI3K/AKT
pathway by phosphorylating IRS-1.
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Introduction
One strain of mice with diminished growth hormone (GH) signaling is the Snell
Dwarf mouse which has a drastic reduction in size. Changes to growth hormone
lead to a cascade of further changes in an organism’s endocrinology. These mutants
have decreased insulin-like growth factor (IGF-1) signaling, lower rates of cancer &
diabetes, and an increase in lifespan by approximately 40% [1]. We have previously
reported that the Snell Dwarf and the GH receptor knockout mouse stocks have con-
stitutive upregulation of a selective form of autophagy known as chaperone-mediated
autophagy (CMA) [2]. Chaperone-mediated autophagy is a cellular process whereby
individual proteins are selectively bound by chaperones and degraded in the lysosome
after being translocated across the lysosomal membrane [3].
Chaperone-mediated autophagy has been found to play several important
roles in the cell. It was first found to be upregulated during prolonged starvation
to recycle amino acids [4], a role similar to other lysosomal degradation pathways
like macroautophagy. Unlike macroautophagy, the selective nature of chaperone-
mediated autophagy enables it to remove oxidized and toxic proteins without dis-
turbing neighboring proteins [5]. It also helps modulate cellular processes by regu-
lating the levels of enzymes and transcription factors [6]. As a result of the roles of
CMA, its dysfunction and misregulation have been implicated in several pathogene-
ses that are associated with age. [7]. Neurodegeneration is a common pathology in
old age that refers to the functional and physical loss of neurons. Alzheimer’s disease
is largely caused by the aggregation of mutant MAPT/Tau protein which forms neu-
rofibrillary tangles and amyloid plaques. Normally, Tau protein is degraded by CMA
while mutant Tau is not able to be entirely internalized for degradation [8]. The two
most common proteins mutated in patients with Parkinson’s disease, α-synuclein and
leucine-rich repeat kinase 2 (LRRK2), have been found to be substrates of CMA [9].
Deficiencies in CMA have been linked to hepatosteatosis [10], Parkinson’s disease,
kidney hypertrophy, and several lysosomal storage disorders [11]. Because of the im-
portance of CMA in cellular homeostasis and in aging-related disease pathogenesis,
it is possible that it may play a role in longevity and healthspan.
The current model of chaperone-mediated autophagy starts with cytosolic
heat-shock chaperone (HSC70) binding a pentapeptide motif of all substrate proteins,
which is necessary [12] and sufficient [13] for CMA. This motif consists of glutamine
(Q) followed by a sequence of a basic, an acidic, a bulky hydrophobic, and then
a repeated basic or bulky hydrophobic residue which most often takes the form of
KFERQ [14]. HSC70 and the substrate protein form a chaperone complex along with
the cochaperones of HIP, HOP, HSP40, HSP90, and BAG-1 [15]. This chaperone
complex brings substrate proteins to a splice variant of a heavily glycosylated type
I integral membrane protein known as lysosomal-associated membrane protein type
2A (LAMP2A) [16]. The monomers of LAMP2A undergo a multimerization process
after binding the chaperone-substrate complex to form a translocation complex that
seems to involve at least two other proteins [17][18]. The LAMP2A complex works
with lumenal HSC70 to unfold and translocate these proteins across the membrane
for degradation by proteolytic enzymes [19].
Regulation of chaperone-mediated autophagy is currently understood to oc-
cur at the molecular level through one primary mechanism. CMA is inhibited by a
lysosomal population of the mammalian target of rapamycin complex 2 (mTORC2)
that phosphorylates AKT at threonine 308 (T308) in the activation loop and serine
2
473 (S473) in the C-terminal hydrophobic motif [20]. AKT is a kinase in the In-
sulin/PI3K/AKT growth signaling axis, which is activated by phosphorylation [21].
One of AKT’s many targets is glial fibrillary acidic protein (GFAP), the primary
positive regulator of CMA. Unphosphorylated GFAP binds LAMP2A to stabilize
the multimerization into the translocation complex. When GFAP is phosphorylated
by AKT, it dissociates from LAMP2A to instead form a complex with elongation
factor 1 alpha (EF1α), which destabilizes the rate-limiting step of CMA in substrate
translocation [22].[23]
Here we report that the use of class I PI3K inhibitors are able to activate
chaperone-mediated autophagy in multiple cell lines via several markers of CMA.
These markers include decreased GFAP phosphorylation and quantification of a flu-
orescent reporter of CMA activity. We also report that these results have been
recapitulated in a heterogenous group of wildtype and Snell dwarf mice.
Results
Earlier work in the Miller lab has found that wild-type mice which are fed after being
fasted show upregulation of AKT phosphorylation at the S473 residue while Snell
dwarf mice do not show the typical robust increase in AKT phosphorlyation, when
they are re-fed after a period of food deprivation (Figure 1A). Akt is activated by
this phosphorylation, which implies that GFAP may be phosphorylated downstream.
To directly measure the effect this has on CMA, we purified lysosomes from Snell
and littermate control mice (Figure 1B). From there, we repeated the fasting and
feeding procedures on both Snell dwarf and wild-type mice. In either the fasted or
fed animals, Snell dwarf mice have reductions in lysosomal GFAP phosphorylation
when compared to control mice (Figure 1C). This genotype effect is significant in the
difference of phosphorylated GFAP levels unlike the fasting effect. We are unsure
as to why the AKT was not found to be affected between Snell and wild-type as it
should be upregulated with the increase in GFAP phosphorylation. Similarly, when
we purified lysosomes from growth hormone receptor knockout (GHKRO) and liver-
specific growth hormone receptor knockout (LiGHRKO) mice, we found that GFAP
phosphorylation was decreased in the former (Figure 1D) and was unchanged in the
latter (Figure 1E). This suggests that global reductions in growth hormone signaling
are required to result in increases in CMA activity.
To further investigate the possibility of AKT regulating GFAP phosphory-
lation and CMA on the lysosome, we looked back at the Insulin/PI3K/AKT growth
signaling axis to find ways of inhibiting AKT. Upstream in the pathway, class 1
phosphoinositide 3-kinases (PI3Ks) act to phosphorylate the 3’-hydroxyl groups of
the phosphatidylinositol embedded in the plasma membrane, PTDINS(4,5)P2, con-
verting it to PTDINS(3,4,5)P3 [24]. This membrane protein acts as a secondary
messenger that allows binding of proteins with a pleckstrein homology (PH) do-
main. Specifically, PDK-1, AKT, and mTORC2 contain PH domains that bind to
PTDINS(3,4,5)P3 enabling phosphorylation of AKT [25].
To ensure that our inhibition of elements of the Insulin/PI3K/AKT path-
way were genuine instead of due to other pathways those elements may be a part of,
we decided to target both PI3K and PDK-1. We originally used three class I PI3K
inhibitors (buparlisib, pictilisib, and copanlisib) and three PDK-1 inhibitors (BX795,
3
Figure 1: ”AKT and GFAP phosphorylation in Snell Dwarf vs. WT mice”
4
Figure 2: ”Class 1 PI3K Inhibitors and PDK-1 Inhibitors Affect GFAP Phosphorylation”
BX912, and GSK2334470). We obtained similar results for all of these drugs, but
only continued on with buparlisib and pictilisib in subsequent experiments. For
those two as well as BX795, we began by finding the optimal dosage of our PI3K
inhibitors (Figure 2A) and our PDK-1 inhibitor (Figure 2B) by looking for a dosage
that completely ablated AKT phosphorylation. In the latter, we only saw complete
ablation of phosphorylation at the T308 site, suggesting other kinases act at the
S473 site which seem to still be dependent on PTDINS(3,4,5)P3. We saw a decrease
in AKT and GFAP phosphorylation in cells treated with buparlisib and pictilisib
while total GFAP levels stayed constant (Figure 2C,D). Similarly, we saw decreased
levels of AKT and GFAP phosphorylation in cells treated with BX795 (Figure 2E,F).
This suggests that elements of the Insulin/PI3K/AKT signaling axis like PI3K and
PDK-1 may be able to regulate chaperone-mediated autophagy on the lysosome.
To determine whether or not decreased GFAP phosphorylation indicated
increased levels of CMA, we performed a pulse-chase experiment using a photo-
switchable fluorescent reporter obtained from the Cuervo lab at Albert Einstein
College of Medicine[26]. When CMA is active, the reporter accumulates on the
lysosomal membrane due to having the KFERQ consensus sequence from RNAse
fused to the reporter. The transfected reporter forms fluorescent punctae that are
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Figure 3: ”Class I PI3K Inhibitors and PDK-1 Inhibitors Affect CMA Activity”
visible via microscopy. Blinded quantifications of punctae were then performed to
relatively compare levels of CMA between the different conditions. We first verified
that the reporter actually measured CMA activity by serum starvation (Figure 3A)
and by knocking down lamp2a (Figure 3B). We observed a significant increase in the
number of punctae when CMA is activated by serum deprivation and a significant
decrease in the number of punctae when lamp2a is knocked down, indicating that the
reporter is able to accurately determine conditions of either increased and decreased
CMA activity. Next, we treated cells transfected with the reporter with our class I
PI3K inhibitors, resulting in a significant increase in the number of lysosomal punctae
in treated cells with no apparent effects to cell morphology or nuclear architecture
(Figure 3C). There is a significant increase in the number of lysosomal punctae in
treated cells (Figure 3D). The increase in CMA activity from PI3K inhibitors seems
to be about the same as that of serum starvation. The PDK-1 inhibitor, BX795, has
similar results in both the microscopic images (Figure 3E) and in the quantifications
(Figure 3F). However, it does seem that the increase in CMA activity is not as
apparent as with either pictilisib or buparlisib.
It is possible that our result of inhibiting the Insulin/PI3K/Akt signaling
axis is cell-type specific, we performed the same procedure for class I PI3K inhibitors
in two other cell lines. Specifically, we looked at AML12 hepatocytes and inter-
medullary collecting duct (IMCD3) cells. We observed very similar results in both of
these cell lines. In AML12, we saw decreases in GFAP phosphorylation with either
buparlisib or pictilisib (Figure 4A). The higher doses that were required to completely
ablate AKT phosphorylation are unexplained but it may be due to AML12 being
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Figure 4: ”The Effects of Class I PI3K Inhibitors is not cell-type specific”
hepatocytes which are capable of producing IGF-1 which can stimulate the pathway
we are trying to inhibit. These drug treatments also resulted in increased number of
punctae for both class I PI3K inhibitors (Figure 4B). When we performed the same
experiments in IMCD3 cells, we again saw decreased GFAP phosphorylation (Figure
4C) and increased levels of punctae (Figure 4D).
Earlier work in the field had examined the potential of PI3K inhibitors in
regulating chaperone-mediated autophagy and came to the conclusion that it did
not have a potent, specific effect on CMA [27]. However, their assay only looked
at general PI3K inhibitors, instead of class-specific ones. This is of importance
as there is one known class III PI3K inhibitor known as vacuolar protein sorting
34 (VPS34) [28]. VPS34 produces PTDINS(3)P which controls membrane docking
and fusion during the formation of autophagic vesicles required for macroautophagy
[29][30]. To ensure that our results are due to properly targeting CMA instead of
macroautophagy, we performed a macroautophagic flux assay to see if our drugs had
any effect of macroautophagy in mIMCD3 cells. By using bafilomycin A, a vacuolar
type H+-ATPase inhibitor[31], we can see that the interaction term between our drugs
are not significant suggesting that class I PI3K inhibitors (Figure 5A,B) do not have
an effect on macroautophagy. However, the class 3 PI3K inhibitor, autophinib, does
have an effect on (Figure 5C). Since then, we have carried out the same procedures
in mice with two of our class I PI3K inhibitors (pictilisib and buparlisib). Lysosomes
isolated from the livers of treated mice show increased binding and uptake of known
CMA substrates. Collectively, this work suggests that insulin signaling plays a role
in regulating CMA.
7
Figure 5: ”Class I PI3K Inhibitors don’t have an effect on macroautophagy”
Beyond this story, we wanted to look for other potential regulators of CMA
that may act to inhibit or activate the Insulin/PI3K/Akt signaling axis. We de-
cided to look into 5’-AMP-activated protein kinase (AMPK) given its function as
a conserved master regulator of energy homeostasis [32] and of several prolongevity
pathways [33] which is also known to inhibit the Insulin/PI3K/Akt signaling axis.
[34]. AMPK is a heterotrimeric with a catalytic α subunit and two regulatory sub-
units in β and γ [35]. The β and γ subunits are regulated by the allosteric binding of
AMP to activate AMPK and also promote phosphorylation of the α subunit at T172
[36]. The catalytic α subunit of AMPK acts on the Insulin/PI3K/Akt signaling axis
through two hypothetical mechanisms. AMPK is known to phosphorylate insulin
receptor substrate 1 (IRS-1) at its S789 site. AMPK may also regulate CMA by
phosphorylating protein phosphotase 2A (PP2A) at both S298 and S336 to activate
PP2A [37] such that it can dephosphorylate and inhibit Akt [38]. To determine the
role that these pathways had on CMA, we treated NIH3T3 cells with the Akt in-
hibitor, afuresertib [39], and the allosteric AMPK activator, A-769662 [40] (Figure
6A,B). ACC1 is a substrate of AMPK which we can see has increased phospho-
rylation in the presence of A-769662. Both afuresertib and A-769662 inhibit the
phosphorylation of the Akt substrate, GSK3β, and the phosphorylation of GFAP.
To confirm that this implied increased levels of CMA, we used our assay from earlier
to see that both afuresertib (Figure 6C) and A-769662 (Figure 6D) result in an in-
crease in the number of punctae compared to the DMSO control (Figure 6E). When
we transfected cells with an siRNA for PP2A, A-769662 was still able to inhibit
Akt phosphorylation (Figure 6F,G) which implies that AMPK acts to inhibit In-
sulin/PI3K/Akt signaling instead through IRS-1. When the procedure was repeated
in primary fibroblasts of mouse tails, we found similar results in terms of IRS-1 and
GFAP phosphorylation (Figure 6H). These results imply that AMPK can upregulate
CMA activity by phosphorylating IRS-1. This provides another target for regulation
of chaperone-mediated autophagy besides class I PI3K on the plasma membrane.
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Figure 6: ”AMPK regulates CMA through IRS-1, and not PP2A”
Materials and Methods
Mouse Husbandry
All mice were housed and cared for in our facilities according to established protocols
that were approved by the University of Michigan’s Animal Care and Use Program.
Cell culture
Mouse NIH3T3 cells were cultured in DMEM with 10% FBS under standard con-
ditions. Mouse AML12 cells were cultured in DMEM:F12 supplemented with 10%
FBS, 10 µg/ml insulin, 5.5 µg/ml transferrin, 5 ng/ml selenium, and 40 ng/ml dex-
amethasone. Mouse IMCD3 cells were cultured in DMEM:F12 with 10% FBS under
standard conditions. Cells were transfected using Lipofectamine 2000 following in-
structions of the manufacturer.
Western Blot Analysis
Tissues were frozen with liquid nitrogen and stored at -70 degrees Celsius. Tis-
sues or cell culture were processed, cell lysates were obtained, and equal amounts
of protein were loaded for Western blot analysis. Antibodies were purchased from
Cell Signaling Technologies (Akt #2920S, pAkt-T308 #4056S, pAkt-S473 #4060S,
GSK3β #12456S, pGSK3β-S9 #5558S, Actin #3700S, mSIN1 #12860S, pSIN1-
T86 #14716S, LC3A/B #12741S, ACC1 #4190S, pACC1-S79 #11818S, AMPKα
#2532S, and pAMPK-T172 #2535S) and from Abcam (LAMP2A ab125068, HSC70
ab51052, ATP5A ab14748, UQCRC2 ab14745, MTCO1 ab14705, GFAP ab7260,
pGFAP-S8 ab3562A, and p62 ab109012).
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Fluorescence Quantification of Punctae
Photoconversion of cells grown on coverslips was carried out with a 405/20 nm LED
array (Norlux) for 5 min using 50 mW/cm2 light intensity. More than 90% of the
cells were viable after the photoconversion. For immunofluorescence, cells grown on
coverslips were fixed in 3% formaldehyde in phosphate buffer saline (PBS), blocked
with 10% FBS, permeabilized with 0.01% of TritonX-100 for 30min and then incu-
bated with the primary and corresponding secondary antibodies diluted in 5% FBS
in PBS.
Statistical Analysis
Unless indicated otherwise, results are presented as mean ± standard error of the
mean (SEM). Statistical tests for genotype, fasting and fed conditions (nutritional),
or interaction effects were assessed by two-way analysis of variance (ANOVA) using
P = 0.05 as the threshold for significant effects. To compare specific effects between
groups, an unpaired t-test was used with P = 0.05 as the criterion for significance.
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